Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MDCO 216

Next Previous
X
Search
Drug Profile

MDCO 216

Alternative Names: AIM; ApoA1 Milano; ESP-24217; ET-216; ETC-216; MDCO-216; r-ApoA-I Milano; rApoA-IM; rApoA-IM protein (dimer)

Latest Information Update: 07 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Esperion Therapeutics; The Medicines Company
  • Class Ischaemic heart disorder therapies; Phosphatidylcholines; Phospholipids
  • Mechanism of Action Apolipoprotein A-I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Coronary artery disease; Coronary artery restenosis

Most Recent Events

  • 06 Jan 2020 The Medicines Company has been acquired by Novartis
  • 07 Nov 2016 Discontinued - Phase-I for Coronary artery disease in USA due to lack of effficacy (IV)
  • 07 Nov 2016 Discontinued - Phase-II for Acute coronary syndromes in Canada, Czech Republic, Netherlands, Poland, Hungary and USA due to lack of effficacy (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top